nodes	percent_of_prediction	percent_of_DWPC	metapath
Thiabendazole—CYP1A1—liver cancer	0.912	1	CbGaD
Thiabendazole—Lansoprazole—CYP1A1—liver cancer	0.00173	1	CrCbGaD
Thiabendazole—CYP1A1—Estrogen Receptor Pathway—PPARA—liver cancer	0.000908	0.0138	CbGpPWpGaD
Thiabendazole—CYP1A2—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—liver cancer	0.000849	0.0129	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL12A—liver cancer	0.00083	0.0126	CbGpPWpGaD
Thiabendazole—CYP1A1—Estrogen Receptor Pathway—ESR1—liver cancer	0.000822	0.0125	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—GSTA2—liver cancer	0.000808	0.0123	CbGpPWpGaD
Thiabendazole—CYP1A1—Estrogen metabolism—GSTM1—liver cancer	0.000807	0.0123	CbGpPWpGaD
Thiabendazole—Hepatic failure—Sorafenib—liver cancer	0.000792	0.0382	CcSEcCtD
Thiabendazole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1H4—liver cancer	0.000749	0.0114	CbGpPWpGaD
Thiabendazole—CYP1A2—Fatty Acid Omega Oxidation—CYP2E1—liver cancer	0.000746	0.0114	CbGpPWpGaD
Thiabendazole—CYP1A1—Cytochrome P450 - arranged by substrate type—NR1H4—liver cancer	0.000746	0.0114	CbGpPWpGaD
Thiabendazole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I3—liver cancer	0.000736	0.0112	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—AHR—liver cancer	0.000705	0.0107	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—AHR—liver cancer	0.000705	0.0107	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—NFE2L2—liver cancer	0.000687	0.0105	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—NFE2L2—liver cancer	0.000687	0.0105	CbGpPWpGaD
Thiabendazole—CYP1A2—Estrogen Receptor Pathway—CYP1A1—liver cancer	0.000633	0.00963	CbGpPWpGaD
Thiabendazole—CYP1A2—Xenobiotics—CYP2E1—liver cancer	0.000624	0.0095	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—HPGDS—liver cancer	0.000616	0.00939	CbGpPWpGaD
Thiabendazole—CYP1A1—Phase 1 - Functionalization of compounds—NR1H4—liver cancer	0.000605	0.00921	CbGpPWpGaD
Thiabendazole—CYP1A2—Tamoxifen metabolism—CYP2E1—liver cancer	0.0006	0.00914	CbGpPWpGaD
Thiabendazole—CYP1A2—Phase II conjugation—UGDH—liver cancer	0.000599	0.00912	CbGpPWpGaD
Thiabendazole—CYP1A2—Aflatoxin activation and detoxification—GGT1—liver cancer	0.000597	0.00909	CbGpPWpGaD
Thiabendazole—CYP1A2—Estrogen Receptor Pathway—PPARA—liver cancer	0.000579	0.00881	CbGpPWpGaD
Thiabendazole—CYP1A1—Arachidonic acid metabolism—HPGDS—liver cancer	0.000577	0.00878	CbGpPWpGaD
Thiabendazole—CYP1A1—Oxidative Stress—HMOX1—liver cancer	0.000575	0.00876	CbGpPWpGaD
Thiabendazole—CYP1A1—Biological oxidations—UGDH—liver cancer	0.00055	0.00837	CbGpPWpGaD
Thiabendazole—Stevens-Johnson syndrome—Sorafenib—liver cancer	0.000544	0.0262	CcSEcCtD
Thiabendazole—CYP1A2—Fatty Acid Omega Oxidation—CYP1A1—liver cancer	0.000536	0.00816	CbGpPWpGaD
Thiabendazole—Jaundice—Sorafenib—liver cancer	0.000535	0.0258	CcSEcCtD
Thiabendazole—CYP1A1—Estrogen Receptor Pathway—JUN—liver cancer	0.000532	0.0081	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12A—liver cancer	0.000529	0.00805	CbGpPWpGaD
Thiabendazole—CYP1A2—Estrogen Receptor Pathway—ESR1—liver cancer	0.000524	0.00798	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—liver cancer	0.000521	0.00793	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—GSTA2—liver cancer	0.000515	0.00785	CbGpPWpGaD
Thiabendazole—CYP1A2—Estrogen metabolism—GSTM1—liver cancer	0.000514	0.00783	CbGpPWpGaD
Thiabendazole—CYP1A1—Tryptophan metabolism—CYP2E1—liver cancer	0.000503	0.00765	CbGpPWpGaD
Thiabendazole—CYP1A2—Estrogen metabolism—CYP1A1—liver cancer	0.000488	0.00743	CbGpPWpGaD
Thiabendazole—CYP1A2—Cytochrome P450 - arranged by substrate type—NR1H4—liver cancer	0.000476	0.00724	CbGpPWpGaD
Thiabendazole—Erythema multiforme—Sorafenib—liver cancer	0.000466	0.0225	CcSEcCtD
Thiabendazole—CYP1A1—Estrogen Receptor Pathway—STAT3—liver cancer	0.00046	0.00701	CbGpPWpGaD
Thiabendazole—CYP1A1—PPARA activates gene expression—NR1H4—liver cancer	0.000459	0.00699	CbGpPWpGaD
Thiabendazole—Tinnitus—Sorafenib—liver cancer	0.000459	0.0222	CcSEcCtD
Thiabendazole—Flushing—Sorafenib—liver cancer	0.000457	0.022	CcSEcCtD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—AHR—liver cancer	0.00045	0.00685	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—AHR—liver cancer	0.00045	0.00685	CbGpPWpGaD
Thiabendazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—NR1H4—liver cancer	0.000449	0.00684	CbGpPWpGaD
Thiabendazole—CYP1A2—Xenobiotics—CYP1A1—liver cancer	0.000448	0.00683	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—NFE2L2—liver cancer	0.000438	0.00667	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—NFE2L2—liver cancer	0.000438	0.00667	CbGpPWpGaD
Thiabendazole—CYP1A1—Arachidonic acid metabolism—GGT1—liver cancer	0.000432	0.00657	CbGpPWpGaD
Thiabendazole—CYP1A2—Tamoxifen metabolism—CYP1A1—liver cancer	0.000431	0.00656	CbGpPWpGaD
Thiabendazole—Liver injury—Epirubicin—liver cancer	0.000431	0.0208	CcSEcCtD
Thiabendazole—CYP1A1—Oxidative Stress—MAPK14—liver cancer	0.000429	0.00654	CbGpPWpGaD
Thiabendazole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—liver cancer	0.000408	0.00621	CbGpPWpGaD
Thiabendazole—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP2E1—liver cancer	0.000406	0.00619	CbGpPWpGaD
Thiabendazole—CYP1A1—Oxidation by Cytochrome P450—CYP2E1—liver cancer	0.000401	0.00611	CbGpPWpGaD
Thiabendazole—Liver injury—Doxorubicin—liver cancer	0.000399	0.0192	CcSEcCtD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—liver cancer	0.000393	0.00599	CbGpPWpGaD
Thiabendazole—Angioedema—Sorafenib—liver cancer	0.000392	0.0189	CcSEcCtD
Thiabendazole—CYP1A2—Phase 1 - Functionalization of compounds—NR1H4—liver cancer	0.000386	0.00587	CbGpPWpGaD
Thiabendazole—Leukopenia—Sorafenib—liver cancer	0.000384	0.0185	CcSEcCtD
Thiabendazole—Coordination abnormal—Epirubicin—liver cancer	0.000369	0.0178	CcSEcCtD
Thiabendazole—CYP1A2—Arachidonic acid metabolism—HPGDS—liver cancer	0.000368	0.0056	CbGpPWpGaD
Thiabendazole—Hepatocellular injury—Epirubicin—liver cancer	0.000362	0.0175	CcSEcCtD
Thiabendazole—CYP1A2—Biological oxidations—UGDH—liver cancer	0.000351	0.00534	CbGpPWpGaD
Thiabendazole—Anaphylactic shock—Sorafenib—liver cancer	0.00035	0.0169	CcSEcCtD
Thiabendazole—CYP1A2—Phase II conjugation—GSTA3—liver cancer	0.000344	0.00524	CbGpPWpGaD
Thiabendazole—Coordination abnormal—Doxorubicin—liver cancer	0.000342	0.0165	CcSEcCtD
Thiabendazole—CYP1A2—Estrogen Receptor Pathway—JUN—liver cancer	0.000339	0.00517	CbGpPWpGaD
Thiabendazole—Hepatocellular injury—Doxorubicin—liver cancer	0.000335	0.0162	CcSEcCtD
Thiabendazole—Anorexia—Sorafenib—liver cancer	0.000334	0.0161	CcSEcCtD
Thiabendazole—CYP1A2—Melatonin metabolism and effects—CYP1A1—liver cancer	0.000333	0.00507	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—liver cancer	0.000332	0.00506	CbGpPWpGaD
Thiabendazole—CYP1A1—Phase 1 - Functionalization of compounds—CYP2E1—liver cancer	0.000329	0.00502	CbGpPWpGaD
Thiabendazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CPT1B—liver cancer	0.000321	0.00489	CbGpPWpGaD
Thiabendazole—CYP1A1—Biological oxidations—NR1H4—liver cancer	0.000321	0.00489	CbGpPWpGaD
Thiabendazole—CYP1A2—Tryptophan metabolism—CYP2E1—liver cancer	0.00032	0.00488	CbGpPWpGaD
Thiabendazole—CYP1A1—Biological oxidations—GSTA3—liver cancer	0.000316	0.00481	CbGpPWpGaD
Thiabendazole—CYP1A2—Phase II conjugation—GSTA4—liver cancer	0.000315	0.00479	CbGpPWpGaD
Thiabendazole—CYP1A1—Metapathway biotransformation—GSTA3—liver cancer	0.000311	0.00474	CbGpPWpGaD
Thiabendazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—NR1H4—liver cancer	0.00031	0.00472	CbGpPWpGaD
Thiabendazole—Lymphadenopathy—Epirubicin—liver cancer	0.000308	0.0149	CcSEcCtD
Thiabendazole—Dyspepsia—Sorafenib—liver cancer	0.000308	0.0149	CcSEcCtD
Thiabendazole—CYP1A2—Phase II conjugation—GSTA2—liver cancer	0.000307	0.00467	CbGpPWpGaD
Thiabendazole—Decreased appetite—Sorafenib—liver cancer	0.000304	0.0147	CcSEcCtD
Thiabendazole—Fatigue—Sorafenib—liver cancer	0.000302	0.0146	CcSEcCtD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—ESR1—liver cancer	0.000299	0.00456	CbGpPWpGaD
Thiabendazole—CYP1A2—Phase II conjugation—GSTA1—liver cancer	0.000296	0.00451	CbGpPWpGaD
Thiabendazole—CYP1A2—Estrogen Receptor Pathway—STAT3—liver cancer	0.000293	0.00447	CbGpPWpGaD
Thiabendazole—Hepatic failure—Epirubicin—liver cancer	0.000293	0.0141	CcSEcCtD
Thiabendazole—CYP1A2—Phase II conjugation—NAT2—liver cancer	0.000293	0.00446	CbGpPWpGaD
Thiabendazole—CYP1A1—Biological oxidations—GSTA4—liver cancer	0.000289	0.0044	CbGpPWpGaD
Thiabendazole—Gastrointestinal pain—Sorafenib—liver cancer	0.000286	0.0138	CcSEcCtD
Thiabendazole—Lymphadenopathy—Doxorubicin—liver cancer	0.000285	0.0138	CcSEcCtD
Thiabendazole—CYP1A1—Metapathway biotransformation—GSTA4—liver cancer	0.000285	0.00434	CbGpPWpGaD
Thiabendazole—CYP1A1—Biological oxidations—GSTA2—liver cancer	0.000281	0.00429	CbGpPWpGaD
Thiabendazole—Abdominal pain—Sorafenib—liver cancer	0.000277	0.0133	CcSEcCtD
Thiabendazole—CYP1A2—Arachidonic acid metabolism—GGT1—liver cancer	0.000275	0.00419	CbGpPWpGaD
Thiabendazole—CYP1A1—Biological oxidations—GSTA1—liver cancer	0.000272	0.00413	CbGpPWpGaD
Thiabendazole—Hepatic failure—Doxorubicin—liver cancer	0.000271	0.0131	CcSEcCtD
Thiabendazole—CYP1A1—Biological oxidations—NAT2—liver cancer	0.000268	0.00409	CbGpPWpGaD
Thiabendazole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—liver cancer	0.000268	0.00408	CbGpPWpGaD
Thiabendazole—CYP1A1—Metapathway biotransformation—NAT2—liver cancer	0.000265	0.00403	CbGpPWpGaD
Thiabendazole—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2E1—liver cancer	0.000259	0.00394	CbGpPWpGaD
Thiabendazole—Hypersensitivity—Sorafenib—liver cancer	0.000258	0.0124	CcSEcCtD
Thiabendazole—CYP1A2—Oxidation by Cytochrome P450—CYP2E1—liver cancer	0.000256	0.00389	CbGpPWpGaD
Thiabendazole—Asthenia—Sorafenib—liver cancer	0.000251	0.0121	CcSEcCtD
Thiabendazole—Pruritus—Sorafenib—liver cancer	0.000248	0.0119	CcSEcCtD
Thiabendazole—Diarrhoea—Sorafenib—liver cancer	0.000239	0.0115	CcSEcCtD
Thiabendazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CRABP1—liver cancer	0.000237	0.00361	CbGpPWpGaD
Thiabendazole—CYP1A2—Phase II conjugation—HPGDS—liver cancer	0.000234	0.00356	CbGpPWpGaD
Thiabendazole—Dizziness—Sorafenib—liver cancer	0.000231	0.0112	CcSEcCtD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1A1—liver cancer	0.00023	0.00351	CbGpPWpGaD
Thiabendazole—CYP1A2—Tryptophan metabolism—CYP1A1—liver cancer	0.00023	0.00351	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—CYP1A1—liver cancer	0.00023	0.00351	CbGpPWpGaD
Thiabendazole—CYP1A1—Metapathway biotransformation—GPX3—liver cancer	0.000225	0.00343	CbGpPWpGaD
Thiabendazole—Vomiting—Sorafenib—liver cancer	0.000222	0.0107	CcSEcCtD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—RAF1—liver cancer	0.000222	0.00338	CbGpPWpGaD
Thiabendazole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—liver cancer	0.000222	0.00337	CbGpPWpGaD
Thiabendazole—Rash—Sorafenib—liver cancer	0.000221	0.0106	CcSEcCtD
Thiabendazole—Dermatitis—Sorafenib—liver cancer	0.00022	0.0106	CcSEcCtD
Thiabendazole—Headache—Sorafenib—liver cancer	0.000219	0.0106	CcSEcCtD
Thiabendazole—CYP1A2—Arachidonic acid metabolism—CYP1A1—liver cancer	0.000215	0.00328	CbGpPWpGaD
Thiabendazole—CYP1A1—Biological oxidations—HPGDS—liver cancer	0.000215	0.00327	CbGpPWpGaD
Thiabendazole—CYP1A2—Phase 1 - Functionalization of compounds—CYP2E1—liver cancer	0.00021	0.0032	CbGpPWpGaD
Thiabendazole—Nausea—Sorafenib—liver cancer	0.000208	0.01	CcSEcCtD
Thiabendazole—Hyperglycaemia—Epirubicin—liver cancer	0.000205	0.0099	CcSEcCtD
Thiabendazole—CYP1A2—Biological oxidations—NR1H4—liver cancer	0.000205	0.00312	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—CDKN1B—liver cancer	0.000203	0.0031	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—CDKN1B—liver cancer	0.000203	0.0031	CbGpPWpGaD
Thiabendazole—Drowsiness—Epirubicin—liver cancer	0.000203	0.00978	CcSEcCtD
Thiabendazole—CYP1A2—Biological oxidations—GSTA3—liver cancer	0.000201	0.00307	CbGpPWpGaD
Thiabendazole—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.000201	0.0097	CcSEcCtD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—liver cancer	0.000199	0.00303	CbGpPWpGaD
Thiabendazole—CYP1A2—Metapathway biotransformation—GSTA3—liver cancer	0.000199	0.00302	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—EPT1—liver cancer	0.000198	0.00302	CbGpPWpGaD
Thiabendazole—Jaundice—Epirubicin—liver cancer	0.000198	0.00953	CcSEcCtD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—liver cancer	0.000194	0.00295	CbGpPWpGaD
Thiabendazole—Haematuria—Epirubicin—liver cancer	0.000193	0.00933	CcSEcCtD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—liver cancer	0.000191	0.0029	CbGpPWpGaD
Thiabendazole—Hyperglycaemia—Doxorubicin—liver cancer	0.00019	0.00916	CcSEcCtD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—CDKN1A—liver cancer	0.000188	0.00286	CbGpPWpGaD
Thiabendazole—Drowsiness—Doxorubicin—liver cancer	0.000188	0.00905	CcSEcCtD
Thiabendazole—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1A1—liver cancer	0.000186	0.00283	CbGpPWpGaD
Thiabendazole—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.000186	0.00897	CcSEcCtD
Thiabendazole—CYP1A2—Biological oxidations—GSTA4—liver cancer	0.000184	0.0028	CbGpPWpGaD
Thiabendazole—CYP1A2—Oxidation by Cytochrome P450—CYP1A1—liver cancer	0.000184	0.0028	CbGpPWpGaD
Thiabendazole—Jaundice—Doxorubicin—liver cancer	0.000183	0.00882	CcSEcCtD
Thiabendazole—CYP1A2—Metapathway biotransformation—GSTA4—liver cancer	0.000182	0.00277	CbGpPWpGaD
Thiabendazole—Hypoaesthesia—Epirubicin—liver cancer	0.000181	0.00874	CcSEcCtD
Thiabendazole—CYP1A2—Biological oxidations—GSTA2—liver cancer	0.000179	0.00273	CbGpPWpGaD
Thiabendazole—Haematuria—Doxorubicin—liver cancer	0.000179	0.00863	CcSEcCtD
Thiabendazole—Visual impairment—Epirubicin—liver cancer	0.000175	0.00846	CcSEcCtD
Thiabendazole—CYP1A2—Phase II conjugation—GGT1—liver cancer	0.000175	0.00267	CbGpPWpGaD
Thiabendazole—CYP1A1—Biological oxidations—CYP2E1—liver cancer	0.000175	0.00266	CbGpPWpGaD
Thiabendazole—CYP1A2—Biological oxidations—GSTA1—liver cancer	0.000173	0.00264	CbGpPWpGaD
Thiabendazole—CYP1A1—Metapathway biotransformation—CYP2E1—liver cancer	0.000173	0.00263	CbGpPWpGaD
Thiabendazole—Erythema multiforme—Epirubicin—liver cancer	0.000172	0.0083	CcSEcCtD
Thiabendazole—CYP1A2—Biological oxidations—NAT2—liver cancer	0.000171	0.00261	CbGpPWpGaD
Thiabendazole—Tinnitus—Epirubicin—liver cancer	0.00017	0.00819	CcSEcCtD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—liver cancer	0.000169	0.00258	CbGpPWpGaD
Thiabendazole—Flushing—Epirubicin—liver cancer	0.000169	0.00815	CcSEcCtD
Thiabendazole—CYP1A2—Metapathway biotransformation—NAT2—liver cancer	0.000169	0.00257	CbGpPWpGaD
Thiabendazole—Hypoaesthesia—Doxorubicin—liver cancer	0.000168	0.00808	CcSEcCtD
Thiabendazole—CYP1A1—PPARA activates gene expression—PPARA—liver cancer	0.000164	0.0025	CbGpPWpGaD
Thiabendazole—Chills—Epirubicin—liver cancer	0.000163	0.00788	CcSEcCtD
Thiabendazole—Visual impairment—Doxorubicin—liver cancer	0.000162	0.00783	CcSEcCtD
Thiabendazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARA—liver cancer	0.000161	0.00245	CbGpPWpGaD
Thiabendazole—CYP1A1—Biological oxidations—GGT1—liver cancer	0.000161	0.00245	CbGpPWpGaD
Thiabendazole—Erythema multiforme—Doxorubicin—liver cancer	0.000159	0.00768	CcSEcCtD
Thiabendazole—CYP1A2—Phase II conjugation—GSTP1—liver cancer	0.000157	0.00239	CbGpPWpGaD
Thiabendazole—Tinnitus—Doxorubicin—liver cancer	0.000157	0.00757	CcSEcCtD
Thiabendazole—Flushing—Doxorubicin—liver cancer	0.000156	0.00754	CcSEcCtD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—MYC—liver cancer	0.000156	0.00237	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—liver cancer	0.000155	0.00236	CbGpPWpGaD
Thiabendazole—Chills—Doxorubicin—liver cancer	0.000151	0.00729	CcSEcCtD
Thiabendazole—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—liver cancer	0.000151	0.0023	CbGpPWpGaD
Thiabendazole—Vision blurred—Epirubicin—liver cancer	0.000149	0.0072	CcSEcCtD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—TNF—liver cancer	0.000145	0.00221	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—liver cancer	0.000145	0.00221	CbGpPWpGaD
Thiabendazole—CYP1A2—Phase II conjugation—GSTM1—liver cancer	0.000145	0.0022	CbGpPWpGaD
Thiabendazole—CYP1A1—Biological oxidations—GSTP1—liver cancer	0.000144	0.0022	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—KRAS—liver cancer	0.000144	0.00219	CbGpPWpGaD
Thiabendazole—CYP1A2—Metapathway biotransformation—GPX3—liver cancer	0.000144	0.00219	CbGpPWpGaD
Thiabendazole—CYP1A1—Metapathway biotransformation—GSTP1—liver cancer	0.000142	0.00217	CbGpPWpGaD
Thiabendazole—Leukopenia—Epirubicin—liver cancer	0.000142	0.00684	CcSEcCtD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—liver cancer	0.000142	0.00215	CbGpPWpGaD
Thiabendazole—Vision blurred—Doxorubicin—liver cancer	0.000138	0.00667	CcSEcCtD
Thiabendazole—Convulsion—Epirubicin—liver cancer	0.000137	0.00662	CcSEcCtD
Thiabendazole—CYP1A2—Biological oxidations—HPGDS—liver cancer	0.000137	0.00208	CbGpPWpGaD
Thiabendazole—CYP1A1—PPARA activates gene expression—PPARG—liver cancer	0.000136	0.00207	CbGpPWpGaD
Thiabendazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—liver cancer	0.000133	0.00203	CbGpPWpGaD
Thiabendazole—CYP1A1—Biological oxidations—GSTM1—liver cancer	0.000133	0.00202	CbGpPWpGaD
Thiabendazole—Leukopenia—Doxorubicin—liver cancer	0.000131	0.00633	CcSEcCtD
Thiabendazole—CYP1A1—Metapathway biotransformation—GSTM1—liver cancer	0.000131	0.00199	CbGpPWpGaD
Thiabendazole—Confusional state—Epirubicin—liver cancer	0.00013	0.00629	CcSEcCtD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—liver cancer	0.00013	0.00197	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—liver cancer	0.00013	0.00197	CbGpPWpGaD
Thiabendazole—Anaphylactic shock—Epirubicin—liver cancer	0.000129	0.00624	CcSEcCtD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—CPT1B—liver cancer	0.000128	0.00195	CbGpPWpGaD
Thiabendazole—Convulsion—Doxorubicin—liver cancer	0.000127	0.00613	CcSEcCtD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—liver cancer	0.000127	0.00193	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—EPT1—liver cancer	0.000127	0.00193	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—liver cancer	0.000123	0.00188	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—NR1H4—liver cancer	0.000123	0.00188	CbGpPWpGaD
Thiabendazole—Anorexia—Epirubicin—liver cancer	0.000123	0.00595	CcSEcCtD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—liver cancer	0.000122	0.00186	CbGpPWpGaD
Thiabendazole—Hypotension—Epirubicin—liver cancer	0.000121	0.00583	CcSEcCtD
Thiabendazole—Confusional state—Doxorubicin—liver cancer	0.000121	0.00582	CcSEcCtD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—liver cancer	0.00012	0.00182	CbGpPWpGaD
Thiabendazole—Anaphylactic shock—Doxorubicin—liver cancer	0.00012	0.00577	CcSEcCtD
Thiabendazole—Somnolence—Epirubicin—liver cancer	0.000115	0.00555	CcSEcCtD
Thiabendazole—Anorexia—Doxorubicin—liver cancer	0.000114	0.0055	CcSEcCtD
Thiabendazole—Dyspepsia—Epirubicin—liver cancer	0.000114	0.00549	CcSEcCtD
Thiabendazole—Decreased appetite—Epirubicin—liver cancer	0.000112	0.00542	CcSEcCtD
Thiabendazole—Hypotension—Doxorubicin—liver cancer	0.000112	0.00539	CcSEcCtD
Thiabendazole—CYP1A2—Biological oxidations—CYP2E1—liver cancer	0.000112	0.0017	CbGpPWpGaD
Thiabendazole—Fatigue—Epirubicin—liver cancer	0.000111	0.00538	CcSEcCtD
Thiabendazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARA—liver cancer	0.000111	0.00169	CbGpPWpGaD
Thiabendazole—CYP1A2—Metapathway biotransformation—CYP2E1—liver cancer	0.00011	0.00168	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—liver cancer	0.000108	0.00164	CbGpPWpGaD
Thiabendazole—Feeling abnormal—Epirubicin—liver cancer	0.000107	0.00514	CcSEcCtD
Thiabendazole—Somnolence—Doxorubicin—liver cancer	0.000106	0.00513	CcSEcCtD
Thiabendazole—Gastrointestinal pain—Epirubicin—liver cancer	0.000106	0.0051	CcSEcCtD
Thiabendazole—Dyspepsia—Doxorubicin—liver cancer	0.000105	0.00508	CcSEcCtD
Thiabendazole—Decreased appetite—Doxorubicin—liver cancer	0.000104	0.00502	CcSEcCtD
Thiabendazole—Fatigue—Doxorubicin—liver cancer	0.000103	0.00498	CcSEcCtD
Thiabendazole—CYP1A2—Biological oxidations—GGT1—liver cancer	0.000102	0.00156	CbGpPWpGaD
Thiabendazole—Abdominal pain—Epirubicin—liver cancer	0.000102	0.00493	CcSEcCtD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—MYC—liver cancer	9.92e-05	0.00151	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—liver cancer	9.9e-05	0.00151	CbGpPWpGaD
Thiabendazole—Feeling abnormal—Doxorubicin—liver cancer	9.86e-05	0.00476	CcSEcCtD
Thiabendazole—Gastrointestinal pain—Doxorubicin—liver cancer	9.78e-05	0.00472	CcSEcCtD
Thiabendazole—Hypersensitivity—Epirubicin—liver cancer	9.53e-05	0.0046	CcSEcCtD
Thiabendazole—Abdominal pain—Doxorubicin—liver cancer	9.46e-05	0.00456	CcSEcCtD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	9.43e-05	0.00144	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—UGDH—liver cancer	9.4e-05	0.00143	CbGpPWpGaD
Thiabendazole—Asthenia—Epirubicin—liver cancer	9.28e-05	0.00448	CcSEcCtD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—liver cancer	9.24e-05	0.00141	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—TNF—liver cancer	9.24e-05	0.00141	CbGpPWpGaD
Thiabendazole—CYP1A2—Biological oxidations—GSTP1—liver cancer	9.2e-05	0.0014	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—liver cancer	9.17e-05	0.0014	CbGpPWpGaD
Thiabendazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—liver cancer	9.16e-05	0.0014	CbGpPWpGaD
Thiabendazole—Pruritus—Epirubicin—liver cancer	9.15e-05	0.00441	CcSEcCtD
Thiabendazole—CYP1A2—Metapathway biotransformation—GSTP1—liver cancer	9.07e-05	0.00138	CbGpPWpGaD
Thiabendazole—Diarrhoea—Epirubicin—liver cancer	8.85e-05	0.00427	CcSEcCtD
Thiabendazole—CYP1A1—Metabolism—EPT1—liver cancer	8.84e-05	0.00135	CbGpPWpGaD
Thiabendazole—Hypersensitivity—Doxorubicin—liver cancer	8.82e-05	0.00425	CcSEcCtD
Thiabendazole—Asthenia—Doxorubicin—liver cancer	8.58e-05	0.00414	CcSEcCtD
Thiabendazole—Dizziness—Epirubicin—liver cancer	8.55e-05	0.00413	CcSEcCtD
Thiabendazole—Pruritus—Doxorubicin—liver cancer	8.47e-05	0.00408	CcSEcCtD
Thiabendazole—CYP1A2—Biological oxidations—GSTM1—liver cancer	8.46e-05	0.00129	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—TAT—liver cancer	8.38e-05	0.00128	CbGpPWpGaD
Thiabendazole—CYP1A2—Metapathway biotransformation—GSTM1—liver cancer	8.34e-05	0.00127	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	8.24e-05	0.00126	CbGpPWpGaD
Thiabendazole—Vomiting—Epirubicin—liver cancer	8.22e-05	0.00397	CcSEcCtD
Thiabendazole—Diarrhoea—Doxorubicin—liver cancer	8.19e-05	0.00395	CcSEcCtD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—CPT1B—liver cancer	8.16e-05	0.00124	CbGpPWpGaD
Thiabendazole—Rash—Epirubicin—liver cancer	8.15e-05	0.00393	CcSEcCtD
Thiabendazole—Dermatitis—Epirubicin—liver cancer	8.15e-05	0.00393	CcSEcCtD
Thiabendazole—Headache—Epirubicin—liver cancer	8.1e-05	0.00391	CcSEcCtD
Thiabendazole—CYP1A2—Biological oxidations—CYP1A1—liver cancer	8.02e-05	0.00122	CbGpPWpGaD
Thiabendazole—Dizziness—Doxorubicin—liver cancer	7.91e-05	0.00382	CcSEcCtD
Thiabendazole—CYP1A2—Metapathway biotransformation—CYP1A1—liver cancer	7.91e-05	0.0012	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—NR1H4—liver cancer	7.86e-05	0.0012	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—liver cancer	7.79e-05	0.00119	CbGpPWpGaD
Thiabendazole—Nausea—Epirubicin—liver cancer	7.68e-05	0.00371	CcSEcCtD
Thiabendazole—Vomiting—Doxorubicin—liver cancer	7.61e-05	0.00367	CcSEcCtD
Thiabendazole—Rash—Doxorubicin—liver cancer	7.54e-05	0.00364	CcSEcCtD
Thiabendazole—Dermatitis—Doxorubicin—liver cancer	7.54e-05	0.00364	CcSEcCtD
Thiabendazole—Headache—Doxorubicin—liver cancer	7.5e-05	0.00362	CcSEcCtD
Thiabendazole—Nausea—Doxorubicin—liver cancer	7.11e-05	0.00343	CcSEcCtD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—GGT1—liver cancer	6.17e-05	0.000939	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	6.01e-05	0.000916	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—UGDH—liver cancer	5.99e-05	0.000913	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—CPT1B—liver cancer	5.7e-05	0.000867	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—GLUL—liver cancer	5.7e-05	0.000867	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—EPT1—liver cancer	5.64e-05	0.000858	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—NR1H4—liver cancer	5.49e-05	0.000836	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—GSTA3—liver cancer	5.4e-05	0.000822	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—TAT—liver cancer	5.34e-05	0.000814	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	5.26e-05	0.0008	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—GSTA4—liver cancer	4.94e-05	0.000752	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—GSTA2—liver cancer	4.81e-05	0.000733	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—GSTA1—liver cancer	4.64e-05	0.000707	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—NAT2—liver cancer	4.59e-05	0.000699	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—PPARA—liver cancer	4.42e-05	0.000672	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—ALDOB—liver cancer	4.4e-05	0.00067	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—CRABP1—liver cancer	4.2e-05	0.000639	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—GGT1—liver cancer	3.93e-05	0.000599	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	3.78e-05	0.000576	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—HPGDS—liver cancer	3.67e-05	0.000559	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—liver cancer	3.65e-05	0.000556	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—CPT1B—liver cancer	3.63e-05	0.000553	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—GLUL—liver cancer	3.63e-05	0.000553	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—NR1H4—liver cancer	3.5e-05	0.000533	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—GSTA3—liver cancer	3.44e-05	0.000524	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	3.32e-05	0.000506	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—ALB—liver cancer	3.28e-05	0.0005	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—PSMA4—liver cancer	3.27e-05	0.000498	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—PSMD10—liver cancer	3.27e-05	0.000498	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—GOT2—liver cancer	3.18e-05	0.000485	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—GSTA4—liver cancer	3.15e-05	0.00048	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	3.08e-05	0.000469	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—GSTA2—liver cancer	3.07e-05	0.000467	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—CYP2E1—liver cancer	2.99e-05	0.000456	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—GSTA1—liver cancer	2.96e-05	0.000451	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—NAT2—liver cancer	2.93e-05	0.000446	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	2.9e-05	0.000441	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—liver cancer	2.82e-05	0.000429	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—ALDOB—liver cancer	2.81e-05	0.000427	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—CYCS—liver cancer	2.8e-05	0.000426	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—GGT1—liver cancer	2.75e-05	0.000418	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—GOT1—liver cancer	2.75e-05	0.000418	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—CRABP1—liver cancer	2.68e-05	0.000408	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—GSTP1—liver cancer	2.47e-05	0.000376	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—HMOX1—liver cancer	2.43e-05	0.000371	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	2.41e-05	0.000367	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—HPGDS—liver cancer	2.34e-05	0.000356	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—liver cancer	2.33e-05	0.000354	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—GSTM1—liver cancer	2.27e-05	0.000345	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	2.12e-05	0.000323	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—ALB—liver cancer	2.09e-05	0.000319	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—PSMD10—liver cancer	2.09e-05	0.000318	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—PSMA4—liver cancer	2.09e-05	0.000318	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—GOT2—liver cancer	2.03e-05	0.000309	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—MTHFR—liver cancer	2e-05	0.000305	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—PPARA—liver cancer	1.97e-05	0.000299	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—CYP2E1—liver cancer	1.91e-05	0.000291	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	1.85e-05	0.000281	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—CYCS—liver cancer	1.79e-05	0.000272	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.77e-05	0.000269	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—GOT1—liver cancer	1.75e-05	0.000267	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—GGT1—liver cancer	1.75e-05	0.000267	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—PIK3CG—liver cancer	1.68e-05	0.000256	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—PPARG—liver cancer	1.63e-05	0.000247	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—GSTP1—liver cancer	1.57e-05	0.00024	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—HMOX1—liver cancer	1.55e-05	0.000236	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—PIK3CD—liver cancer	1.48e-05	0.000225	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—ALB—liver cancer	1.46e-05	0.000223	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—GSTM1—liver cancer	1.45e-05	0.00022	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—CYP1A1—liver cancer	1.37e-05	0.000209	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—PIK3CB—liver cancer	1.29e-05	0.000196	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—MTHFR—liver cancer	1.28e-05	0.000195	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—PPARA—liver cancer	1.25e-05	0.000191	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.13e-05	0.000171	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—PIK3CG—liver cancer	1.07e-05	0.000163	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—PPARG—liver cancer	1.04e-05	0.000158	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—PIK3CD—liver cancer	9.44e-06	0.000144	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—ALB—liver cancer	9.32e-06	0.000142	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—PIK3CB—liver cancer	8.23e-06	0.000125	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—PIK3CA—liver cancer	7.87e-06	0.00012	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—AKT1—liver cancer	6.43e-06	9.78e-05	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—PIK3CA—liver cancer	5.02e-06	7.64e-05	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—AKT1—liver cancer	4.1e-06	6.24e-05	CbGpPWpGaD
